Mounjaro: The branded, FDA-approved injectable tirzepatide, primarily for Type 2 Diabetes
Candidates are typically individuals who: Struggle with weight loss despite diet and exercise Want support with appetite control and cravings Are seeking a medically supervised approach to wellness Meet provider eligibility guidelines after consultation All patients must complete a medical intake and consultation with a licensed provider prior to treatment
But even with restrictions in place, the GLP-1 market and prescribing rates are expected to grow
Financing Options: This product qualifies for Katapult financing
IVs are administered directly into the bloodstream supervised by medical professionals, bypassing the digestive system, which allows for better absorption and quicker effects
Both generic products began shipping to Canadian pharmacies on May 20, 2026, resetting what "cheapest semaglutide" means in this country